Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
Langermann S,
Möllby R,
Burlein JE,
Palaszynski SR,
Auguste CG,
DeFusco A,
Strouse R,
Schenerman MA,
Hultgren SJ,
Pinkner JS,
Winberg J,
Guldevall L,
Söderhäll M,
Ishikawa K,
Normark S,
Koenig S.
MedImmune, Inc., Gaithersburg, MD 20878, USA. langermanns@medimmune. com
Escherichia coli FimH adhesin mediates binding to the bladder mucosa. In mice, a FimH vaccine protects against bacterial challenge. In this study, 4 monkeys were inoculated with 100 microgram of FimCH adhesin-chaperone complex mixed with MF59 adjuvant, and 4 monkeys were given adjuvant only intramuscularly. After 2 doses (day 0 and week 4), a booster at 48 weeks elicited a strong IgG antibody response to FimH in the vaccinated monkeys. All 8 monkeys were challenged with 1 mL of 108 E. coli cystitis isolate NU14. Three of the 4 vaccinated monkeys were protected from bacteruria and pyuria; all control monkeys were infected. These findings suggest that a vaccine based on the FimH adhesin of E. coli type 1 pili may have utility in preventing cystitis in humans.
PMID: 10669375 [PubMed - indexed for MEDLINE]